Type 1 diabetes market to reach $9.9 bn in 7MM by 2033
Express Pharma
JANUARY 2, 2025
The late-stage T1D pipeline consists of several agents, including Eli Lillys insulin efsitora alfa, which is anticipated to launch in 2027.
STAT+: Pharmalittle: We’re reading about unsupported drug price hikes, an annual HIV prevention shot, and more
STAT
DECEMBER 12, 2024
Such a medicine, if proven effective, would be the closest thing to a vaccine the HIV field has produced in four decades of research. The company plans to begin the trial next year, with an eye toward regulatory filings in late 2027.
Join 11,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Trending Sources
FDA Approves Immunoglobulin Formulation With Low IgA Content for Primary Immunodeficiency
Pharmacy Times
JULY 7, 2025
Takeda will discontinue Gammagard S/D by December 2027, transitioning to the new low IgA formulation. Takeda has informed the FDA that the manufacturing of Gammagard S/D will cease in December 2027.
Taletrectinib Gains FDA Approval for Locally Advanced or Metastatic ROS1+ NSCLC
Pharmacy Times
JUNE 11, 2025
Completion Date (Estimated): June 2027 “For people living with advanced ROS1+ lung cancer, who tend to be diagnosed at a younger age, having another treatment option can make a real difference for them and their loved ones,” Janet Freeman-Daily, cofounder and president of The ROS1ders, said in a news release.
Piramal Pharma announces $90m investment to expand US sites
Pharmaceutical Technology
JULY 1, 2025
How will RFK Jr’s American dream for vaccines play out? The expansion will be concluded by late 2027, with production capacity increasing from 104 batches annually at peak utilisation to more than 240 batches.
Vor, with new CEO, changes course to target autoimmune disease
BioPharma Dive
JUNE 26, 2025
Data from that trial is expected in 2027. “I says US won’t donate to global vaccine effort View all Events 07 JUL Webinar | 10 a.m. Vor is paying RemeGene $45 million upfront along with $80 million in warrants to purchase common stock in exchange for the drug, called telitacicept. Europe and South America, according to the companies.
Merck concludes SpringWorks acquisition for $3.4bn
Pharmaceutical Technology
JULY 2, 2025
How will RFK Jr’s American dream for vaccines play out? The merger, announced in April 2025 , will positively impact Merck’s financial position by contributing to revenues immediately, and is anticipated to be accretive to its earnings per share by 2027.
FDA approves Takeda’s Gammagard liquid ERC for primary immunodeficiency
Pharmaceutical Technology
JULY 1, 2025
How will RFK Jr’s American dream for vaccines play out? Takeda anticipates commencing commercialisation efforts for Gammagard liquid ERC in the US by 2026, with plans to follow suit in the European Union (EU) by 2027. GlobalData Strategic Intelligence US Tariffs are shifting - will you react or anticipate?
Sarepta to lay off about 500 employees after Duchenne gene therapy setbacks
BioPharma Dive
JULY 16, 2025
The company also has $1 billion in senior notes coming due in 2027. The company believes sales in ambulatory patients are likely to annualize at a minimum of $500 million annually through 2027. Three other “exon-skipping” drugs Sarepta sells for Duchenne could bring in about $900 million per year over that period, the company added.
17th edition of CPHI & PMEC India inaugurated at India Expo Centre, Noida
Express Pharma
NOVEMBER 26, 2024
Namit Joshi, Vice Chairman, Pharmexil, said, “The Indian pharmaceutical industry has solidified its global position as the ‘Pharmacy of the World’ and earned recognition as the ‘Healers of the World’ through its exceptional contribution to COVID-19 vaccine distribution. With exports nearing $27.84
Looking for Clues about FDA Under RFK Jr.
FDA Law Blog: Biosimilars
JANUARY 29, 2025
Aside from his many high profile claims about vaccines, what he perceives as corruption at FDA, and his promise to go wild on health, Kennedys specific policy preferences about how FDA should administer its day-to-day oversight of drugs, medical devices, food, dietary supplements, cosmetics, or tobacco have not been publicly detailed.
WHO endorses Gilead’s Yeztugo for HIV prevention
Pharmaceutical Technology
JULY 14, 2025
How will RFK Jr’s American dream for vaccines play out? The WHO says that the vaccine offers a highly effective, long-acting alternative to daily oral pills and other shorter-acting options. The approval of Yeztugo was hailed as a historical breakthrough by HIV experts and charities. Sign up for our daily news round-up!
MSD shares drop 5% amid plans for $3bn cost cutting strategy
Pharmaceutical Technology
JULY 29, 2025
Merck & Co (MSD) has joined fellow big pharma companies in looking to redirect cash, as the drugmaker revealed plans to save $3bn annually by the end of 2027. Pfizer and BMS both have programmes set to save $1.5bn and $2bn, respectively, by 2027. Credit: HJBC via Shutterstock. Don’t let policy changes catch you off guard.
Sanofi agrees to invest $25m in Adagene
Pharmaceutical Technology
JULY 2, 2025
How will RFK Jr’s American dream for vaccines play out? With the additional funds from Sanofi’s investment and current assets on hand, it anticipates sufficient funds to sustain its planned operations in 2027. As of December 2024, the company reported cash reserves of $85.2m.
Biocryst sells Europe business; Peter Marks criticizes new FDA vaccine rules
BioPharma Dive
JUNE 27, 2025
Deep Dive Library Events Press Releases Topics Sign up Search Sign up Search Pharma Biotech FDA Clinical Trials Deals Drug Pricing Gene Therapy An article from News roundup Biocryst sells Europe business; Peter Marks criticizes new FDA vaccine rules Biocryst is offloading part of its business to an Italian drugmaker for $250 million upfront.
Novavax reaches settlement with UK Health Security Agency over COVID-19 vaccine agreement
Express Pharma
NOVEMBER 5, 2024
Novavax said on Tuesday that it has entered into a termination and settlement agreement with the UK Health Security Agency (UKHSA) related to its COVID-19 vaccine supply agreement. million over a three-year period, ending on June 30, 2027, a filing showed. Novavax has agreed to refund $123.8 The first installment payment is due on Nov.
Could bispecifics unseat Keytruda from its oncology throne?
PharmaVoice
JULY 28, 2025
Final results from these trials won’t be released until 2027 or 2028, although there will likely be some earlier signals from interim data. Both studies pit the drug directly against Keytruda, not a placebo as in the original trial. This will help answer the bigger question: Can it replace Keytruda?” Smith said.
Gilead to test once-a-year HIV prevention shot
STAT
DECEMBER 11, 2024
Such a medicine, if proven effective, would be the closest thing to a vaccine the HIV field has produced in four decades of research. The company plans to begin the trial next year, with an eye toward regulatory filings in late 2027. Read the rest…
Sarepta Therapeutics to cut 500 jobs amid restructuring
Pharmaceutical Technology
JULY 17, 2025
How will RFK Jr’s American dream for vaccines play out? Find out more After its strategic review, the company aims to focus on high-impact programmes to meet its 2027 financial obligations and support long-term viability. It also announced an update regarding its Elevidys label changes for Duchenne muscular dystrophy (DMD) treatment.
Manufacturing facility expansion to advance next-gen vaccine
European Pharmaceutical Review
MARCH 14, 2024
Overall, the goal of expanded facility is to strengthen [SK biosciences] manufacturing capabilities for global supply [of the pneumococcal conjugate vaccine candidate GBP410]” SK bioscience has announced its manufacturing plant L HOUSE, in Andong, Gyeongsangbuk-do, South Korea, is set to have a facility expansion.
Pfizer’s Covid-19 vaccine sales forecasts upgraded with sales of $37bn in 2022
Pharmaceutical Technology
FEBRUARY 21, 2023
Pfizer and BioNTech’s Covid-19 vaccine, Comirnaty, had a phenomenal year with forecast sales of $37bn in 2022. Comirnaty is the leading prophylactic vaccine for Covid-19 and is expected to generate an additional $2.8bn in sales in 2022 compared to GlobalData’s H1 2022 forecast. Comirnaty is the first globally approved Covid-19 vaccine.
Bavarian Nordic secures $156.8m US vaccine deal
Pharmaceutical Business Review
AUGUST 9, 2024
Additionally, the contract includes around $17m for additional services from 2025 to 2027, which encompasses the storage of vaccine doses within the US. The vaccine, known as MVA-BN or Modified Vaccinia Ankara-Bavarian Nordic, is marketed under various brand names, JYNNEOS, IMVANEX, and IMVAMUNE.
Covid-19 vaccine success bolsters nanoparticle drug delivery research
Pharmaceutical Technology
APRIL 24, 2023
Since then, the field of nanomedicine has steadily progressed to reach high points such as the successful use of nanotechnology to deliver messenger RNA (mRNA)-based Covid-19 vaccines. In the case of most mRNA vaccines, a lipid nanoparticle-based approach was chosen due to its ability to protect the mRNA in the body and prevent degradation.
STAT+: Moderna touts research progress as it cuts R&D spending by $1.1 billion
STAT
SEPTEMBER 12, 2024
billion, between 2024 and 2027 in a concession to investors who have viewed the company’s outlays following its pandemic-era windfall as profligate. Moderna said Thursday it would cut its annual spending on research and development by 23%, or $1.1
Rapid microbiology testing market growth expected 2022 to 2027
European Pharmaceutical Review
MARCH 27, 2023
percent between 2022 and 2027. ” Growing focus on drug and vaccine discovery and development, recent advances in biotechnology and pharmaceutical research and the presence of several US market players offering a wide range of microbial testing products are aiding the growth of the market, the report found. and rqMicro AG.
STAT+: Pharmalittle: We’re reading about Moderna R&D cuts, Lilly plant investments and more
STAT
SEPTEMBER 12, 2024
billion, between 2024 and 2027 in a concession to investors who have viewed the company’s outlays following its pandemic-era windfall as profligate, STAT writes. So here are some items of interest. Have a great day, everyone. … Moderna plans to cut its annual spending on research and development by 23%, or $1.1
NHC Provides Input on Patient Engagement in Medicare Drug Price Negotiations
Putting Patients First Blog
SEPTEMBER 20, 2024
The legislation included multiple provisions related to Medicare drug coverage including a $2000 cap on out-of-pocket drug costs, a $35/month insulin cap, and improved access to adult vaccines. Earlier this year CMS released draft guidance for Initial Payment Applicability Year (IPAY) 2027.
HPAPI contract manufacturing to value $14.6 billion by 2030
European Pharmaceutical Review
OCTOBER 18, 2022
However, during the second half, the surge in demand for vaccines to fight the coronavirus enhanced the industry’s need for raw materials and product intermediates of API molecules. Global pharma contract manufacturing market to value $120bn by 2027… The post HPAPI contract manufacturing to value $14.6
UK follows through on doubling of statutory scheme rate
pharmaphorum
JUNE 11, 2025
next year and 26% in 2027 – which the ABPI pointed out is "well over three times what is required in Germany…and four times the average payment rate in France." The rate for the latter half of the year brings the full-year average to 23.4% – rising to 24.3%
Lilly surges on positive phase 3 readout from diabetes contender
pharmaphorum
DECEMBER 10, 2020
Shares in the big US pharma were up nearly 6% following the announcement, although the pharma stocks in general were buoyed by optimism over BioNTech/Pfizer’s COVID-19 vaccine. Tirzepatide is also taken weekly, cutting the number of injections needed to control blood sugar.
Turning the TIDE: oligonucleotide development trends
European Pharmaceutical Review
APRIL 14, 2023
Article – oligonucleotide therapeutics: The promise of telomerase inhibitors for treating blood cancer … Dr Leberer also discussed the number of drugs approved in the space: Currently, 18 are oligonucleotide drugs, with mRNA vaccines holding the same number, he noted. Eight target the liver and four target muscle.
Merck obtains favourable US court ruling on sitagliptin patent lawsuit
Pharmaceutical Technology
SEPTEMBER 23, 2022
It will expire on 24 November 2026, and the paediatric exclusivity lasts until 24 May 2027. In June, the company received approval from the FDA for a pneumococcal 15-valent conjugate vaccine , Vaxneuvance, for children aged between six weeks and 17 years. The suit involved two Merck patents.
Injectable Drug Delivery 2022
pharmaphorum
FEBRUARY 3, 2022
There is a rising demand for vaccines, insulin, and many modern medicines used to treat cancer and other chronic diseases. reaching £915 billion by 2027. The injectable drug delivery market is expected to rise at a compound annual growth rate of 12.9%
Pre-Filled Syringes East Coast 2022
pharmaphorum
JANUARY 18, 2022
million in 2020 and with the rapid growth of the industry, is expected to grow at a CAGR of 8.95% up to 2027. Device innovations, connected delivery and regulatory guidance for advanced parenteral systems. The global pre-filled syringes market was valued at $1139.6
APAC overview: trends, challenges, and possibilities for growth in the MarTech sector
Pharma Mirror
JANUARY 26, 2023
billion by 2027. Within the region, the Indian market shows impressive success, responsible for 80% of anti-retroviral drugs and 50% of the global supply of vaccines. At the same time, Asia-Pacific pharma players expect their businesses to grow rapidly in the upcoming year. billion in 2022.
Pack Expo Las Vegas Marks 30th Anniversary with New Experiences for 2025
PharmaTech
JULY 22, 2025
COVID-19 mRNA vaccine production platform. PMMI continues building long-term industry engagement, recognizing more than 100 companies from the original 1995 show and announcing five future Pack Expo events through 2027. Pharmaceutical manufacture background with glass bottles with clear liquid on automatic conveyor line. References 1.
Key developments in pharmaceutical manufacturing – September 2023
European Pharmaceutical Review
OCTOBER 12, 2023
With the goal of supplying cell therapies, vaccines and other essential medicines such as antibody drugs to patients, the facilities aim to address major supply challenges and navigate the intricacies of producing fragile biological products. Meath opened last month. In total, both projects represent an investment of over €1 billion.
High biologics demand spurs need for greater contract manufacturing
Pharmaceutical Technology
APRIL 24, 2023
Demand for biologics, including vaccines, is at an all-time high, in the post-Covid era. There are fewer sites for cell and gene therapies and vaccines – 90 companies with 127 facilities, as per GlobalData figures. The approval of the mRNA Covid-19 vaccine, which is a biologic, has thrust the modality even further into the spotlight.
Pfizer’s €1.2 billion manufacturing site expansion
European Pharmaceutical Review
DECEMBER 2, 2022
The facility is planned for completion in 2027. Cork all produce medicines and vaccines for arthritis, inflammation, cancer, anti-infectives, haemophilia, pain and stroke. The project is in the initial design phase, with construction expected to commence on the site in 2024. Kildare and Ringaskiddy, Co.
LNP Formulation and Process Development in Pharma | April 12-14 2022
pharmaphorum
JANUARY 27, 2022
The global nanopharmaceutical drugs market, catalyzed by the success of Pfizer/BioNTech and Moderna’s mRNA vaccines, is poised to reach US$82.7 billion by 2027. This is your chance to explore the use of alternative polymer lipids to maximize scalability and moving towards cGMP manufacturing for pipeline progression.
Moderna will cut $1.1bn off its annual R&D spend
pharmaphorum
SEPTEMBER 12, 2024
billion a year from 2027, reversing years of growth made possible by sales of its COVID-19 vaccines. Moderna is showcasing its R&D pipeline to investors today, but the headline news is a decision to cut its R&D spend by a massive $1.1
Apples to apples: Stelara biosimilars and the fight for market share
BioPharma Dive
JULY 21, 2025
While adalimumab biosimilars have captured approximately one-third of the market today, experts predict they will reach 60% by the end of 2027. This move opened the floodgates for other distribution partnerships and Humira began losing significant market share.
Nine for 2023, part two: healthcare’s hard problem, the prognosis for diagnosis, and key new pharmacotherapy platforms
pharmaphorum
JANUARY 16, 2023
Rapid growth is forecasted from 2023 onwards: some industry observers predict that the global POC and rapid Dx market projected to reach $75bn by 2027, up from $45bn in 2022, at a CAGR of 10.7%. Innovation will power the market. The fundamental engine of innovation for the global pharmaceutical industry continues.
Delivery systems for biologics
European Pharmaceutical Review
MARCH 4, 2024
These biopharmaceuticals encompass a range of products including vaccines, recombinant therapeutic proteins, tissues, cells and gene therapies – all sourced from living organisms. percent through 2027. 8,9 In contrast to virus-based vectors and VLPs, another viable approach is the use of non‑viral vectors for gene and protein delivery.
Let's personalize your content